Diabetes and Metabolic Syndrome: Clinical Research and Reviews is the official journal of DiabetesIndia and the National Diabetes, Obesity and Cholesterol Foundation (NDOC).

Diabetes and Metabolic Syndrome: Clinical Research and Reviews aims to reach out to healthcare professionals, diabetes educators and other stakeholders, providing them with a global platform to submit their research on diabetes care. The journal publishes research covering various aspects of diabetes and related diseases like cardiovascular diseases, diabetic neuropathy, weakening eyesight, sexual dysfunction, management of diabetes mellitus, obesity, insulin management and metabolic syndrome, among others.

The journal publishes peer-reviewed original articles, reviews, short communication, case reports, letter to the Editor and expert comments. Reviews and mini-reviews are especially welcomed for those areas within endocrinology undergoing rapid changes.

AUDIENCE

Endocrinologists, cardiologists and internists.

IMPACT FACTOR

2022: 10.000 © Clarivate Analytics Journal Citation Reports 2023

ABSTRACTING AND INDEXING

Scopus
Emerging Sources Citation Index (ESCI)
Embase
PubMed/Medline
PubMed/Medline
EBSCOhost
Current Abstracts (EBSCO)
TOC Premier
EDITORIAL BOARD

Editor in Chief

Anoop Misra, Fortis C-DOC Hospital for Diabetes and Allied Sciences, Department of Diabetes, New Delhi, India
Obesity, Diabetes, Insulin resistance, Liver fat, Cardiovascular risk

Managing Editor

Banshi Saboo, Diabetes India, Indian Academy of Diabetology, Ahmedabad, India
Internal Medicine, Diabetes

Associate Editors

Sosale R. Aravind, Diona Hospital, Bengaluru, India
Nutrition and Dietetics, Internal Medicine (General Medicine), Diabetology

Manish Bansal, Medanta The Medicity, Gurgaon, India
Atherosclerotic vascular disease, Preventive cardiology, Lipid disorders, Echocardiography, Strain imaging

Saurav Basu, Indian Institutes of Public Health, New Delhi, India
Diabetes epidemiology, Epidemiology, Adherence, Public Health, Prevention, Community Health, Observational Research, Operations Research, Implementation Research

Deep Dutta, CEDAR Superspecialty Healthcare, Delhi, India
Endocrinology

Stuart Gray, University of Glasgow College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom

Scott Grundy, The University of Texas Southwestern Medical Center, Department of Clinical Nutrition, Dallas, United States of America
Cholesterol Metabolism, Dietary Fats, Drugs Affecting Lipoprotein Metabolism, Human Genetics, Metabolic Syndrome

Ritesh Gupta, Fortis CDOC Hospital for Diabetes and Allied Sciences, New Delhi, India
Diabetes, Male Sexual Dysfunction

Philip Home, Newcastle University, Newcastle, United Kingdom
Diabetes, Male Sexual Dysfunction

Vikash Jaiswal, Larkin Community Hospital, Miami, United States of America
Cardiovascular disease, diabetes, disparities among races, metabolic disorders, meta-analysis

Ranji Jayawardena, University of Colombo, Faculty of Medicine, Colombo, Sri Lanka
Clinical Nutrition, obesity

Shashank Joshi, Lilavati Hospital, Department of Diabetology, Mumbai, India
Endocrinology, Internal Medicine

Mohammad Kuchay, Medanta The Medicity, Gurgaon, India
Nonalcoholic fatty liver disease in people with diabetes, Glucose-lowering drugs and nonalcoholic fatty liver disease, Metabolic syndrome and related conditions, Polycystic ovary syndrome

Sanjeev Kumar, Oklahoma University Health Science Centre, Department of Medicine Endocrinology, Oklahoma City, United States of America
Diabetes, Metabolic Syndrome, Obesity, Cardiovascular disorders

Jagmeet Madan, Sir Vithaldas Thackersey College of Home Science, Mumbai, India

Abbas Malandish, Urmia University, Department of Exercise Physiology, Urmia, Iran
Exercise Physiology, Sports Cardiology, Diabetes and Metabolic Syndrome, Heart Failure, Biomarkers, Inflammatory Markers, Cellular and Molecular Biology

Prasenjit Mitra, Post Graduate Institute of Medical Education and Research, Department of Biochemistry, Chandigarh, India
Diabetes, Metabolic syndrome, Biomarkers Extracellular vesicles

Mahmoud Nassar, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, United States of America
Internal Medicine, Endocrine, Diabetes, Quality management, hospital administration and public policy

Yashdra Sethi, Government Doon Medical College, Dehradun, India
Diabetes, Cardiology, Endocrinology, Cardio-metabolism, Metabolic Syndrome, Precision Medicine, Personalized Medicine, Artificial Intelligence, Computational cardiology, Endocrine Tumors

Sushum Sharma, Saudi German Hospital Dubai, Dubai, United Arab Emirates
Internal Medicine, Diabetes, Hypertension, Obesity

Awadhesh Kumar Singh, GD Hospital & Diabetes Institute, Kolkata, India
Diabetes, Metabolic disorders, Obesity, Endocrinology, Meta-analysis

Sathish Thirunavukkarasu, Emory University School of Medicine, Atlanta, United States of America
Epidemiology of type 2 diabetes, prevention of type 2 diabetes, diabetes complications, precision medicine for prevention of type 2 diabetes, lifestyle interventions, health economics, health systems research, implementation science, and advanced statistical methods

Naval K. Vikram, All India, Institute of Medical Sciences, Department of Medicine, New Delhi, India
Obesity, Non-alcoholic fatty liver disease

Editorial Board

Alfredo Adolfo Reza-Albarrán, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Ciudad de México, Mexico
Hayder Al-Aubaidy, La Trobe University, Melbourne, Australia
Harpreet Singh Bajaj, LMC Healthcare, Toronto, Canada
Suchitra Behl, Henry Ford Health System, Detroit, United States of America
Sumit Roy Chowdhury, All India Institute of Medical Sciences, New Delhi, India
Jayant Dey, Endocrine and Metabolic Disorders Institute, Tupelo, United States of America
Amerta Ghosh, Fortis C-DOC Hospital, New Delhi, India
Mohamed Hassanein, Dubai Health Authority, Dubai, United Arab Emirates
Akhtar Hussain, Nord University, Boda, Norway
Deepa Iyengar, McGovern Medical School at UTHealth, Houston, United States of America
Sisitha Jayasinghe, University of Tasmania, Hobart, Australia
Ishwarlal Jialal, University of California Davis, Davis, United States of America
Partha Kar, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom
Jothydev Kesavadev, Jothydev's Diabetes & Research Centre, Thiruvananthapuram, India
Pramod Khosla, Wayne State University, Detroit, United States of America
Neetu Mishra, Symbiosis International (Deemed University), Pune, India
Ranjita Mishra, West Virginia University, Morgantown, United States of America
Barakatun-Nisak Mohd Yusof, Putra Malaysia University, Serdang, Malaysia
Sunder Mudaliar, University of California San Diego, La Jolla, United States of America
Satinath Mukhopadhyay, Institute of Postgraduate Medical Education and Research, Kolkata, India
Megha Nataraj, Manipal, India
Ike S. Okosun, Georgia State University, Atlanta, United States of America
Itamar Raz, Hadassah Medical Center Diabetes Unit, Jerusalem, Israel
Naveed Sattar, University of Glasgow, Glasgow, United Kingdom
Krishna G. Seshadri, Apollo Hospitals Chennai Greams Road, Chennai, India
S.K. Singh, Banaras Hindu University, Varanasi, India
Gumpeny Ramachandra Sridhar, Endocrine and Diabetes Centre, Visakhapatnam, India
Sandeep Tak, Dr Sampurnanand Medical College, Jodhpur, India
Raju Vaishya, Indraprastha Apollo Hospitals Institutes of Orthopaedics, New Delhi, India
Nayla Cristina do Vale Moreira, University of Oslo, Oslo, Norway
Krishnaswami Vijayaraghavan, The University of Arizona, Tucson, United States of America
A.H. Zargar, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India
GUIDE FOR AUTHORS

INTRODUCTION
In addition to general articles on clinical aspects of diabetes mellitus, *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* also presents articles on basic research in all areas of diabetes and the metabolic syndrome. Topics include prevention, diagnosis, pathogenesis, clinical management of diabetes and all its complications, including neuropathy, retinopathy, nephropathy, peripheral vascular disease, foot problems (amongst others), as well as atherosclerotic cardiovascular disease. All aspects of disorders associated with the metabolic syndrome with a special emphasis on clinical aspects (prevalence, pathogenesis, risk factors management and prevention, etc.) of comorbid conditions such as hypertension, obesity, dyslipidemias and atherosclerotic cardiovascular disease are also of relevance to the journal. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* also publishes papers on the general pathogenesis and prevention of diabetes.

Criteria for initial considerations for papers submitted will be originality, statistical rigour, and relevance to the aims of the journal. All manuscripts of interest will be subjected to the process of peer review. Initially all submissions are reviewed internally by members of the Editorial Board and all submissions which pass this stage are then subjected to an external peer-review process. Please include names and contact details for six individuals as suggested reviewers for the manuscript, for use at the Editors’ discretion.

Journal Principles
All manuscripts submitted to *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* should report original research not previously published or being considered for publication elsewhere, make explicit any conflict of interest, identify sources of funding and generally be of a high ethical standard.

Submission of a manuscript to this journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may be edited to improve clarity and expression. Submission of a paper to *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* is understood to imply that it has not previously been published and that it is not being considered for publication elsewhere.

There is no publication fees

Essential title page information

Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.

Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main affiliation address. Superscript Arabic numerals are used for such footnotes

When submitting the revised manuscript, please make sure that you upload the final version of the paper. Please remove the old version(s) of the manuscript before submitting the revised version.

Patients and Study Participants

Studies on patients or volunteers require ethics committee approval and informed consent which should be documented in your paper.

Patients have a right to privacy. Therefore identifying information, including patient's photographs, pedigree, images, names, initials, or hospital numbers, should not be included in the submissions unless the information is essential for scientific purposes and written informed consent has been
obtained for publication in print and electronic form from the patient (or parent, guardian or next of kin). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to the journal on request.

Even where consent has been given, identifying details should be omitted if they are not essential. Complete anonymity is difficult to achieve. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

**Article Types**

**Editorials**

These are either written or commissioned by the Editors and should not exceed 1000 words (not including a maximum of 20 references; one small figure can be included).

**Commentaries**

They (1000 words not including a maximum of 20 references and one small figure) offer a stimulating, journalistic and accessible insight into issues of common interest. They are usually commissioned by the Editors but unsolicited articles will be considered. Debates comprise two commentaries of opposing or contrasting opinion written by two different groups of authors. Controversial opinions are welcomed as long as they are set in the context of the generally accepted view.

**Original Research Articles**

These should be a maximum of 5000 words. The word limit includes a maximum of five figures or tables with legends, but does not include up to 50 references and an abstract of up to 200 words structured according to Aims, Methods, Results, Conclusions and Keywords. Divide the manuscript into the following sections: Title Page; Structured Abstract; Introduction; Subjects, Materials and Methods; Results; Discussion; Acknowledgements; References; figures and tables with legends.

**Brief Reports**

These reports should not exceed 1000 words, including a summary of no more than 50 words (but not including up to 20 references) and may be a preliminary report of work completed, a final report or an observation not requiring a lengthy write-up.

**Review articles**

Review articles should be a maximum of 5000 words, including a summary of no more than 100 words (not including up to 75 references) with subheadings in the text to highlight the content of different sections. Reviews are generally commissioned by the Editors but unsolicited articles will be considered.

**Letters to the Editor**

These should be no more than 400 words.

**BEFORE YOU BEGIN**

**Ethics**

Work on human beings that is submitted to the journal should comply with the principles laid down in the Declaration of Helsinki "Recommendations guiding physicians in biomedical research involving human subjects", adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964 (and its successive amendments). The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed. Studies involving experiments with animals must state that their care was in accordance with institution guidelines.
**Conflict of Interest**
Authors should complete the declaration of interest statement using [https://declarations.elsevier.com/](https://declarations.elsevier.com/) and upload to the submission system at the Attach/Upload Files step. Note: Please do not convert the .docx template to another file type. Author signatures are not required. If there are no interests to declare, please choose: "Declarations of interest: none" in the template. More Information.

**Declaration of generative AI in scientific writing**
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s [AI policy for authors](https://www.elsevier.com/locate/dsx).

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

**Disclosure instructions**
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

**Statement:** During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

**Submission declaration**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

**Preprints**
Please note that preprints can be shared anywhere at any time, in line with Elsevier’s [sharing policy](https://www.elsevier.com/locate/dsx). Sharing your preprints e.g. on a preprint server will not count as prior publication (see ‘Multiple, redundant or concurrent publication’ for more information).

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns (“clinicians, patients/clients”) as default/wherever possible to avoid using “he, she,” or “he/she.” We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". When
suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

**Reporting sex- and gender-based analyses**

**Reporting guidance**

For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

**Definitions**

Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the resources on this page offer further insight around sex and gender in research studies.

**Clinical Trials**

All randomised controlled trials submitted to *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* whose primary purpose is to affect clinical practice (phase 3 trials) must be registered in accordance with the principles outlined by the International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org/). ICMJE-approved registries currently include the following: 'ClinicalTrials.gov'; 'www.ISRCTN.org'; 'www.actr.org.au'; 'www.umin.ac.jp'; and 'www.trialregister.nl'. Please include the unique trial number and registry name on manuscript submission.

**Article transfer service**

This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. More information.

**Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If
excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

*Elsevier supports responsible sharing*
Find out how you can share your research published in Elsevier journals.

**Language**
The language of the journal is English. Upon request, Elsevier will direct authors to an agent who can check and improve the English of their paper (prior to submission).

**Publisher Services**
Proofs will be sent to the authors for careful checking. Corrected proofs should be returned to the publisher within stated deadlines.

Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication. Subsequent corrections will not be possible, so please ensure your communication is complete.

Fast-track Publication: The journal aims for prompt publication of all accepted papers. Submissions containing new and particularly important data may be fast-tracked for peer review and publication; this is a limited facility and is strictly at the discretion of the Editors.

Page Charges are not made.

**Submission**
We have now upgraded our submission system to Editorial Manager. Our online submission system guides you stepwise through the process of entering your article details and uploading your files. Editable article files (e.g., Word, LaTeX) are mandatory to use in the peer-review process and typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

**PREPARATION**

**Queries**
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

**Peer review**
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

**Title Page**
On the title page, include title; subtitle (if any); first name, middle initial, and last names of each author, with academic degrees; name of Department(s) and Institution(s) to which the work should be attributed; name and address of author to whom requests for reprints should be sent. The address, telephone and fax numbers of the person responsible for negotiations concerning the manuscripts
should be listed separately and clearly labelled as such. Authors will be required to sign a statement conferring the manuscript copyright to *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*.

**Abstract and Keywords**
A structured abstract of 100 to 250 words for articles (including Reviews), or 50 to 100 words for Brief Communications, should be provided. It should cover the main factual points, including statements of the problem, methods, results, and conclusions. The abstract should be accompanied by a list of three to five keywords for indexing purposes.

**Main Text**
Headings and subheadings should be provided in the Methods and Results sections, and where appropriate in the discussion. Please keep the text clear, concise and free of jargon.

**Keywords**
Immediately after the abstract, provide a minimum of 3 keywords to maximum of 12 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Highlights**
Highlights should contain minimum 2 points and maximum 4 points with a maximum of 125 characters per point including spaces.

**Abbreviations, Numbers and SI Units**
Authors should limit the use of abbreviations. Terms which are mentioned frequently may be abbreviated but only if this does not detract from reader comprehension. The abbreviation should be defined after the first use of the term.

Measurements of length, height, weight and volume should be reported in metric units. Temperatures should be given in degrees Celsius and blood pressures in millimetres of mercury or kPa with the alternative unit in parentheses. All other measurements including laboratory measurement should be reported in the metric system in terms of the International System of Units (SI).

**Drug Names**
Generic names should be used. Proprietary names may be given (parenthetically) with the first use of the generic name.

**Figures**
Figures must be suitable for high-quality reproduction. Lettering should be complete, of professional quality, and of a size appropriate to that of the illustration or drawing, with the necessary reduction in size taken into account. If, together with your accepted article, you submit usable colour figures, Elsevier will ensure that these figures appear free-of-charge in colour in the electronic version of your accepted article. Colour illustrations can only be included in print if the additional cost of reproduction is contributed by the author: you will receive information regarding the costs from Elsevier after receipt of your accepted article.

**Tables**
Tables should be numbered consecutively with Arabic numerals. Provide a short descriptive heading and explanation above each table with a legend. Symbols for units should be confined to column headings. Abbreviations should be kept to a minimum, and when used, explained fully.

**References**
Number the references in the order in which they first appear in the text and identify the reference numbers in the text in superscript. References must be placed at the end of the manuscript. Please use recent references as much as possible. The responsibility for accuracy of references lies with the respective authors. The Journal is in agreement with the International Committee of Medical Journal Editors (http://www.icmje.org). The general arrangement, abbreviations of Journal names and punctuations followed are as per the Uniform Requirements for Manuscripts submitted to Biomedical Journals (http://www.icmje.org). Please pay attention to the style of references and punctuations as follows:

*Journal article*
List all authors when six or less as shown in the example below:

When there are seven or more authors, list only the first six and add et al.


**Book or monograph**


**Data references**

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

**Preprint references**

Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

**Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary Files**

Authors may submit additional supportive applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier web products, including ScienceDirect: https://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file.

**Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.
For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Research Elements**
This journal enables you to publish research objects related to your original research – such as data, methods, protocols, software and hardware – as an additional paper in a Research Elements journal.

Research Elements is a suite of peer-reviewed, open access journals which make your research objects findable, accessible and reusable. Articles place research objects into context by providing detailed descriptions of objects and their application, and linking to the associated original research articles. Research Elements articles can be prepared by you, or by one of your collaborators.

During submission, you will be alerted to the opportunity to prepare and submit a manuscript to one of the Research Elements journals.

More information can be found on the Research Elements page.

**Data statement**
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**AFTER ACCEPTANCE**

**AUTHOR INQUIRIES**
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com